With Claimed Perfecting Feature In Contents (e.g., Excipient, Lubricant, Etc.) Patents (Class 424/465)
  • Patent number: 10653663
    Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: May 19, 2020
    Assignee: DAE HWA PHARMA. CO., LTD.
    Inventors: In-Hyun Lee, Min-Hee Son, Yeong-Taek Park, Seul-Ae Lee, Han-Koo Lee
  • Patent number: 10646447
    Abstract: The present invention relates to an oral sustained-release triple layer tablet, more particularly, a triple layer tablet consisting of an inner immediate-release layer containing a pharmaceutically active ingredient and two outer layers containing swellable polymers. Upon exposure to aqueous media, the two outer layers swell to form gelled layers surrounding the lateral side of the inner layer rapidly, thereby control effectively the release of the pharmaceutically active ingredient from the inner immediate-release layer.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: May 12, 2020
    Assignee: GL PHARMTECH CORP.
    Inventors: Jun Sang Park, U-Hun Song, Ji-Yeon Sim
  • Patent number: 10639340
    Abstract: A method for drying to increase the useful life of botanicals and shorten the time to market after harvest of the botanicals. The method may include flash freezing the botanicals, at a desired optimal temperature range, soon after harvest. The method may include storing the frozen botanicals indefinitely prior to drying. The method may include drying the frozen botanicals using a lyophilizer at a desired optimal temperature and pressure.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 5, 2020
    Inventor: Eric Young
  • Patent number: 10638778
    Abstract: A method for producing powderized cannabis oil, and the resulting powderized cannabis oil, in which concentrated cannabis oil is mixed with and absorbed by a modified starch powder, preferably maltodextrin, in a ratio of at least three grams of starch powder for every one-eighth of a gram of cannabis oil is disclosed. Further disclosed are beverages, baked goods and single-serve beverage brewing cartridges utilizing or incorporating the powderized cannabis oil to create human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 5, 2020
    Assignee: Pivot Pharmaceuticals US Inc.
    Inventors: Ross M. Franklin, Ed Rosenthal, Rachel M. Franklin
  • Patent number: 10624888
    Abstract: Extended release, abuse deterrent dosage forms comprising crush-resistant controlled-release particles that provide abuse deterrent properties to the dosage forms. The crush-resistant controlled-release particles, which comprise plastic/elastic polymers and at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, are prepared by a hot melt extrusion process.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 21, 2020
    Assignee: SpecGX LLC
    Inventors: Jonathan Gaik, Jaehan Park, Ryan Lathrop, Gary Nichols, John Schallom
  • Patent number: 10603279
    Abstract: The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: March 31, 2020
    Assignee: The University of Liverpool
    Inventors: Marco Norman Giardiello, Thomas Oliver McDonald, Andrew Owen, Steven Paul Rannard, Philip John Martin, Darren Lee Smith, James Long
  • Patent number: 10603312
    Abstract: The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: March 31, 2020
    Assignee: Durect Corporation
    Inventors: Su Il Yum, Jaymin Shah, Sung Yun Kwon, Xiaoping Song
  • Patent number: 10596119
    Abstract: Disclosed herein are treatments for diseases such as sleep apnea, hyperuricemia, autistic spectrum disorder (ASD) and other brain disorders using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: March 24, 2020
    Inventor: Salim Shah
  • Patent number: 10568841
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: February 25, 2020
    Assignee: PURDUE PHARMA L.P.
    Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
  • Patent number: 10561618
    Abstract: The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: February 18, 2020
    Assignee: Contera Pharma ApS
    Inventors: John Bondo Hansen, Mikael S. Thomsen, Jens D. Mikkelsen, Peter Gudmund Nielsen, Mads Kreilgaard
  • Patent number: 10555906
    Abstract: Provided are solid oral/per os formulations that include a single cannabinoid, combination of cannabinoids, cannabis extract and combination of cannabis plant constituents. Also provided are methods of making the formulations, as well as therapeutic applications in the treatment and alleviation of various human disorders and/or conditions.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: February 11, 2020
    Assignees: GELPELL AG, SATIPHARM AG
    Inventors: Hagit Sacks, Tomas Edvinsson
  • Patent number: 10537583
    Abstract: An oral formulation, and preparation method and use thereof; the oral formulation comprises 1-50 parts by weight of an A-nor-5a-androstane compound, 20-95 parts by weight of a filling agent, 0-20 parts by weight of a disintegrant, 0.1-30 parts by weight of a binder, 0.1-5 parts by weight of a lubricant and 0.1-5 parts by weight of a glidant. The oral formulation has a high stability and a good dissolution performance.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: January 21, 2020
    Inventor: Yajun Chen
  • Patent number: 10525059
    Abstract: The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: January 7, 2020
    Assignee: Fresenius Kabi Oncology, Ltd.
    Inventors: Rajesh Khanna, Neeraj Kumar, Vijay Kumar Sharma, Ankit Gaur, Dhiraj Khattar
  • Patent number: 10517829
    Abstract: The present invention provides extended release pharmaceutical compositions structured for once a day administration comprising skeletal muscle relaxant such as cyclobenzaprine or its pharmaceutically acceptable salt thereof that extends the release of the drug under in-vitro conditions for at least 8 to 12 hours. The invention also provides process for the preparation of such structured compositions.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: December 31, 2019
    Assignee: INVENTIA HEALTHCARE LIMITED
    Inventors: Sunil Beharilal Jaiswal, Vaibhavi Ankur Shah, Sunil Deviprasad Tiwari
  • Patent number: 10507180
    Abstract: Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: December 17, 2019
    Assignee: AcelRx Pharmaceuticals, Inc.
    Inventors: Pamela Palmer, Thomas Schreck, Stelios Tzannis, Larry Hamel, Andrew I. Poutiatine
  • Patent number: 10493035
    Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: December 3, 2019
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Sean Mark Dalziel, Naveen Bejugam, Nazila Habibizad, Ali Komeyli, DeMei Leung
  • Patent number: 10478413
    Abstract: The present invention relates to a high adhesion dermal therapeutic system comprising an adhesive polymeric matrix with a salt of Diclofenac.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: November 19, 2019
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Giovanni Gennari, Anna Maria Zanellato, Patrizia Santi, Cristina Padula
  • Patent number: 10471056
    Abstract: The invention relates to a dosage form that is suitable for releasing an active ingredient over a long period of time. For this purpose, the active ingredient is released in two-stages in order to do away with an excessively frequent ingestion of the dosage form. The dosage forms according to the invention are for treating dizziness in humans. They are administered with or after a meal. The concept according to the invention provides that the pharmaceutical form has a dimensionally stable portion which, after ingestion of the dosage form by the patients, does not dissolve in the chyme-filled stomach for a number of hours. In this way, this dimensionally stable portion remains in the stomach until same is evacuated by the so-called “housekeeper waves”. Another portion of the dosage form is formed in such a way that it dissolves within a short time of the patients ingesting same. In this way, a quick invasion of the active ingredient with corresponding plasma levels is ensured.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 12, 2019
    Assignee: HENNIG ARZNEIMITTEL GMBH & CO. KG
    Inventors: Jan Christoph Grewe, Karl-Heinz Przyklenk
  • Patent number: 10463623
    Abstract: The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: November 5, 2019
    Assignee: RUBICON RESEARCH PRIVATE LIMITED
    Inventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi, Rupali Kedar Suvarnapathaki
  • Patent number: 10434067
    Abstract: Provided are a solid composite formulation for oral administration, the solid composite formulation including: an ezetimibe granules-part including ezetimibe, said ezetimibe having a particle size distribution wherein the average particle size d(0.9) for the bottom 90% is about 10 ?m or less; and a rosuvastatin mixture-part including rosuvastatin or a pharmaceutically acceptable salt thereof, and a method of preparing the composite formulation.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: October 8, 2019
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Hyun Cho, Jin Cheul Kim, Yong Il Kim, Seung Jun Lee, Jae Hyun Park, Jong Soo Woo
  • Patent number: 10406105
    Abstract: Pharmaceutical formulation in the form of agglomerates comprising A) an excipient content composed of a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of a disintegrant, c) 1-15% by weight of water-insoluble, film-forming polymers d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients the total of the components a) to e) being 100% by weight, and B) at least one active ingredient.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: September 10, 2019
    Assignee: BASF SE
    Inventors: Karl Kolter, Michael Schönherr, Silke Gebert, Kathrin Meyer-Böhm, Angelika Maschke
  • Patent number: 10391103
    Abstract: Disclosed are a ferroporphyrin solid dispersion, preparation method therefor and a pharmaceutical composition comprising the solid dispersion, wherein the weight ratio of ferroporphyrin to the carrier material in the dispersion is 1:1-1:10. The solid dispersion of the present invention masks the undesirable taste of ferroporphyrin, ameliorates irritation thereof to the digestive tract, and at the same time increases the solubility thereof and improves the bioavailability thereof.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: August 27, 2019
    Assignee: SINOTHERAPEUTICS INC.
    Inventors: Larry Yun Fang, Jiansheng Wan, Kun Li, Maojian Gu
  • Patent number: 10369108
    Abstract: The presently disclosed subject matter is directed to a granule, wherein the granule has an active agent and a wax dispersed therein, and the granule exhibits excellent friability when compressed to form a pharmaceutical composition. The subject matter disclosed herein is also directed to methods of preparing the granules and the pharmaceutical compositions comprising the granules. The compositions and methods disclosed provide granules and pharmaceutical compositions for immediate release of the active agent and do not substantially prolong the release of the active agent from the granule.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 6, 2019
    Assignee: Mylan Laboratories, Inc.
    Inventors: Chaoju Xiao, Boyong Li
  • Patent number: 10328029
    Abstract: The present invention relates to oral pharmaceutical compositions comprising nitisinone, or a pharmaceutically acceptable salt thereof, their use in the treatment of tyrosinemia, such as Hereditary Tyrosinemia type-1 (HT-1), or alkaptonuria. The compositions have improved stability characteristics. The invention also relates to processes for producing nitisinone.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: June 25, 2019
    Assignee: CYCLE PHARMACEUTICALS LTD
    Inventors: James Harrison, Stephen Fuller, Tobias Josef Brown
  • Patent number: 10323226
    Abstract: A bacteria starter material for use in biomass generators without causing jamming of the feeder mechanism, particularly under high temperature and/or high humidity conditions, the starter material comprising one or more species of waste-decomposing bacteria, sucrose, and a soy based protein. Preferably, DI-PAC® sugar (sucrose and maltodextrin) and powdered KIKKOMAN® Soy Sauce are used as the sugar and protein ingredients. The starter material may also comprise a dried bran culture comprising Pseudomonas. The starter material ingredients are blended together and formed into a tablet or pellet having a particular shape, size, and hardness characteristics suitable for use in the feeder mechanism of a biomass generator.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 18, 2019
    Assignee: NCH Corporation
    Inventors: Judith G. Pruitt, Robert C. Pearce, III, Daniel Aberle, Charles J. Greenwald, Gabriel F. K. Everett
  • Patent number: 10323056
    Abstract: The present invention relates to non-stoichiometric crystalline hydrates of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: June 18, 2019
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Lovro Selic, Andreas Hotter, Christoph Langes, Ulrich Griesser
  • Patent number: 10314788
    Abstract: An oral pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in a monolithic dosage form, wherein the dosage form is configured such that when the dosage form is divided into more than one piece and at least one of the pieces is administered to a subject the Cmax, AUC, and/or rate of drug released after administration is substantially the same or lower and the Tmax is higher than the Cmax, AUC, rate of drug released, and/or Tmax after administration of: (1) a comparable composition in intact dosage form of equal drug dosage of the administered at least one piece; (2) a bioequivalent drug composition in an intact dosage form of equal drug dosage to the administered at least one piece; and (3) a divided piece of a bioequivalent drug composition, wherein the divided piece comprises a drug dosage equal to the dosage of the administered piece of the oral composition. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: June 11, 2019
    Assignee: INSPIRION DELIVERY SCIENCES LLC
    Inventors: Manish S. Shah, Ray J. Difalco
  • Patent number: 10292966
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: May 21, 2019
    Assignee: Wyeth LLC
    Inventors: Eric J. Benjamin, Wendy A. Dulin, Yanning Lin, Kai Zhuang
  • Patent number: 10271551
    Abstract: A wiping composition and a wiping product containing the composition are disclosed. The wiping composition contains a combination of an antimicrobial agent with a preservative enhancing agent that not only provides antiseptic properties when applied to an adjacent surface, but also is well suited to preserving the substrate that is used to apply the composition. In particular, the composition has been unexpectedly found to inhibit or destroy bacteria, particularly Burkholderia cepacia, even when the active ingredients are used at extremely low levels.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 30, 2019
    Assignee: Lonza Inc.
    Inventors: Angela Marie Sangirardi, Susan Ahrendt Mills, Vito Thomas Cataldo
  • Patent number: 10265301
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: April 23, 2019
    Assignee: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. Miller, Justin M. Keen, Sandra U. Kucera
  • Patent number: 10258577
    Abstract: Disclosed is a multilayer solid pharmaceutical dosage form, wherein a core containing an active ingredient is coated with a first sustained-release coating layer, a drug layer containing the active ingredient is applied onto the first layer, and a second sustained-release coating layer is applied onto the drug layer.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: April 16, 2019
    Assignee: NOVAST LABORATORIES LTD
    Inventors: Yisheng Chen, Guohua Zhang, Manman Liu
  • Patent number: 10231936
    Abstract: Delivery of a drug is controlled to impart a delay before release after administration by formulating the drug with a disruption agent to provide a core, and coating the core with a regulatory membrane comprising a water-soluble gel-forming polymer and a water-insoluble film-forming polymer.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: March 19, 2019
    Assignee: Euro-Celtique S.A.
    Inventors: Derek Allan Prater, Mohammed Hassan, Christopher Robert Bland
  • Patent number: 10232045
    Abstract: The present invention is directed to film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain a water-soluble polymer and guar gum. The film coating compositions can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the water-soluble polymer is a cellulosic or vinyl polymer. Aqueous suspensions containing the inventive film coating compositions and the coated substrates themselves are also disclosed. The resulting coated substrates have relatively low coefficients of static and dynamic friction on wet surfaces rendering them easier to swallow than prior art compositions.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: March 19, 2019
    Assignee: BPSI HOLDINGS LLC
    Inventors: Jeffrey R. Gimbel, Daniel To, Jason Teckoe
  • Patent number: 10220063
    Abstract: Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis, including extracted compounds, synthetic forms, and derivatives thereof. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: March 5, 2019
    Inventor: Dennis M. Jenn
  • Patent number: 10207093
    Abstract: The present invention discloses multiple approaches to preventing the capsule walls and other material from interfering with the performance of an electronic device once the device is activated by surrounding fluid. In accordance with the teachings of the present invention, a miniature ingestible device (MID) may be created using excipients and films. The MID, in accordance with various aspects of the present invention, will have a coating or laminating surrounding an electronic device and separating and isolating the device from the pharmaceutical product or drug within the capsule once the capsule is ingested as well as from the capsule itself as the capsule walls begin to collapse during the disintegration process.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: February 19, 2019
    Assignee: PROTEUS DIGITAL HEALTH, INC.
    Inventors: Timothy Robertson, Hooman Hafezi, Raymond Schmidt
  • Patent number: 10182993
    Abstract: Described herein are controlled release oral pharmaceutical compositions for delivering active pharmaceutical ingredients to the colon and methods for making the same. In particular, an oral pharmaceutical composition comprising a soft capsule and a controlled release matrix for delivering active pharmaceutical ingredients to the colon are described.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: January 22, 2019
    Assignee: Patheon Softgels Inc.
    Inventors: Chue Hue Yang, Tatyana Dyakonov, George Vamvakas, Aqeel A. Fatmi
  • Patent number: 10172944
    Abstract: An excipient composition having good bulk density and improved flow characteristics is provided. The present invention particularly provides a coprocessed excipient composition and a method of producing the same. The coprocessed excipient comprises cellulose derived polymer and a deagglomerated coprocessing agent. The coprocessing agent is fumed silica, colloidal silica or silicon dioxide. The coprocessed excipient is prepared in a continuous process and has excellent compactability and improved flow property as measured by Johanson flow rate number increase from 1.1 to 5.0 fold, is characterized by a Brookfield cohesion factor of less than 0.2 kPa and a bulk density of at least 0.249 g/ml.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: January 8, 2019
    Assignee: ISP INVESTMENTS LLC
    Inventors: Divya Tewari, Yevgeniya A. Titova, Brad Beissner, Thomas Durig
  • Patent number: 10166185
    Abstract: The present invention is directed to an excipient which can be used to manufacture tablets containing oily active ingredients such as oily drugs, and pharmaceutical compositions containing the same.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: January 1, 2019
    Assignee: J. Rettenmaier & Söhne GmbH + Co KG
    Inventors: Anthony Carpanzano, Michael Nagel
  • Patent number: 10154963
    Abstract: Disclosed herein are controlled-release (GR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulation comprising an effective amount of Torsemide or a pharmaceutically acceptable salt thereof and at least one sustained release excipient comprising a polymer, wherein the at least one matrix component is selected from the group consisting of: hydroxy propyl cellulose (HPC), hydroxpropyl methyl cellulose (HPMC), glyceryl behenate, and a polyethylene glycol glyceride. Torsemide may be present in the formulation in a range of about 1 wt % to about 20 wt %, or about 5 wt % to about 10 wt % and the matrix component is present in the formulation in a range of about 5 wt % to about 50 wt %, or about 15 wt % to about 35 wt %. The formulation may further comprise at least one binder, lactose, talc and magnesium stearate. Methods of making and using the controlled-release oral dosage Torsemide formulation are also disclosed. A novel mechanism for Torsemide action in diuresis is further disclosed.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: December 18, 2018
    Assignee: SARFEZ PHARMACEUTICALS, INC.
    Inventor: Salim Shah
  • Patent number: 10143656
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 4, 2018
    Inventors: Mark vB. Cleveland, Edmund V. Dennett, Jr., Russell W. Pelham
  • Patent number: 10111869
    Abstract: The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: October 30, 2018
    Assignee: ETHYPHARM
    Inventors: Catherine Herry, Maryline Boyer, Francoise Vauzelle-Kervroedan, Pascal Oury
  • Patent number: 10098861
    Abstract: The present invention relates to a pharmaceutical composition comprising a sodium benzoate compound and clozapine; and a method for preventing, treating and/or reducing the risk of a neuropsychiatric disorder by administering such pharmaceutical composition.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: October 16, 2018
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang
  • Patent number: 10081636
    Abstract: Methods are provided for efficient preparation of hydromorphone or hydrocodone by redox isomerization of morphine or codeine allylic alcohols, respectively, using transition metal aminophosphine catalysts formed in situ.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: September 25, 2018
    Assignee: Cody Laboratories, Inc.
    Inventors: Gnel Mkrtchyan, Iouri Voitsekhovski, Scott Michaels
  • Patent number: 10071068
    Abstract: Sustained release oral dosage forms of an R-baclofen prodrug are disclosed.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: September 11, 2018
    Assignee: XENOPORT, INC.
    Inventors: David E. Edgren, David J. Kidney, Nikhil Pargaonkar, Derrick K. Kim, Gorm Yoder, Sarni Karaborni
  • Patent number: 10039285
    Abstract: Particulate ceragenin materials may be manufactured by (i) providing a ceragenin feed material comprised of ceragenin molecules, each having a sterol backbone and a plurality cationic groups attached thereto; (ii) fracturing the ceragenin feed material in a milling apparatus to produce a ceragenin particulate material having a particle size distribution with a median particle size in a range from 5 nm to 20 ?m; and (iii) during fracturing, maintaining the ceragenin feed with a moisture content of less than or equal to 10% by weight.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 7, 2018
    Assignee: Brigham Young University
    Inventors: Paul B. Savage, Carl Genberg
  • Patent number: 10034865
    Abstract: Disclosed are pharmaceutical compositions, e.g., in the form of tablets, containing a therapeutically effective amount of an HIV protease inhibitor, e.g., ritonavir, a pharmaceutically acceptable aqueous-soluble polymer, and an erosion-enhancing agent having a particle size distribution in the range of about 1 ?m to about 350 ?m, wherein the composition is substantially free or free of surfactant. Methods of making the compositions, and methods of using them to treat HIV infection are also provided.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: July 31, 2018
    Assignee: Kashiv Pharma, LLC
    Inventors: Navnit H. Shah, Atsawin Thongsukmak, Jaydeep Vaghashiya, Dipen Desai, Wantanee Phuapradit
  • Patent number: 10016359
    Abstract: A solid dosage form of meloxicam containing an acid and sugars or polyalcohols or a mixture thereof.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: July 10, 2018
    Assignee: ALPEX PHARMA SA
    Inventors: Federico Stroppolo, Shahbaz Ardalan
  • Patent number: 10016367
    Abstract: The present invention relates to a cellulose powder usable for a satisfactory orally disintegrating tablet having excellent compression moldability and well-balanced tablet moldability and disintegration properties, which can obtain excellent ingestion feel without feeling roughness and dryness in the oral cavity, and more particularly to a cellulose powder with an average polymerization degree of 150 to 450, an average particle diameter of not less than 10 ?m but less than 100 ?m, and a primary particle ratio of 50% or more.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: July 10, 2018
    Assignee: ASAHI KASEI KABUSHIKI KAISHA
    Inventors: Naoya Yoshida, Yasuhiko Ono, Kazuhiro Obae
  • Patent number: 9962367
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: May 8, 2018
    Assignee: Obseva S.A.
    Inventors: Andre Chollet, Oliver Pohl
  • Patent number: 9956201
    Abstract: Described are compositions that may be orally administered that comprise a bioreversible derivative of hydroxy N-substituted-2-aminotetralin or an enantiomer or salt or prodrug thereof, and a pharmaceutically acceptable carrier suitable for oral administration in the amount present, wherein the composition is orally bioavailable when administered to a subject. The bioreversible derivative has an intrinsic lipophilicity C log P value of about 7 to about 11.5. A method comprises oral administering such composition to a human subject in need of hydroxy N-substituted-2-aminotetralin therapy.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: May 1, 2018
    Assignee: SPRIASO LLC
    Inventors: William I. Higuchi, Firoozeh Aminian Patel